Document is current
Any future updates will be listed below
-
Authors
Kashanian, Sarah M.
Holtzman, Noa G. https://orcid.org/0000-0002-5706-1109
Patzke, Ciera L. https://orcid.org/0000-0002-8566-4345
Cornu, Jonathan
Duffy, Alison https://orcid.org/0000-0002-9018-3722
Koka, Madhurima https://orcid.org/0000-0002-0457-8489
Niyongere, Sandrine https://orcid.org/0000-0001-9254-0095
Duong, Vu H. https://orcid.org/0000-0003-0278-7727
Baer, Maria R. https://orcid.org/0000-0002-9499-1348
Apata, Jummai https://orcid.org/0000-0001-6733-6914
Kamangar, Farin https://orcid.org/0000-0003-4169-7978
Emadi, Ashkan https://orcid.org/0000-0003-3769-3210
-
Funding
Funding for this research was provided by:
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (P30CA134274)
The State of Maryland’s Cigarette Restitution Fund
- License Information
-
More Information
Article History
Received: 24 September 2020
Accepted: 25 February 2021
First Online: 7 March 2021
Declarations
:
: AE: research grants from Jazz Pharmaceuticals, Servier and NewLink Genetics, global oncology advisory board member for Amgen and has served as an advisory board member for Genentech and Servier. AD: Amgen Speaker Bureau, a consultant for Heron Therapeutics and Teva Pharmaceuticals. All other authors declare that they have no relevant competing interests.
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. The Institutional Review Board at the study center approved this study. As this was a retrospective study, informed consent could not be obtained from all patients included in the study.
: Not applicable.
